These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22863956)

  • 1. [Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma].
    Yamashita T; Kaneko S
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1335-45. PubMed ID: 22863956
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
    Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
    J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma.
    Ishizaki M; Kaibori M; Matsui K; Ikeda H; Yoshida K; Okazaki K; Kariya S; Tanigawa N; Nakatake R; Matsushima H; Sakaguchi T; Kon M
    Cancer Invest; 2017 Apr; 35(4):271-276. PubMed ID: 28272913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
    He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
    Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
    Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
    Ikeda M; Shimizu S; Sato T; Morimoto M; Kojima Y; Inaba Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T
    Ann Oncol; 2016 Nov; 27(11):2090-2096. PubMed ID: 27573564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular targeted agent for hepatocellular carcinoma].
    Ueshima K; Kudo M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():457-62. PubMed ID: 23520633
    [No Abstract]   [Full Text] [Related]  

  • 10. [Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
    Tsukamoto T; Kanazawa A; Shimizu S; Murata A; Sakae M; Kurihara S; Tashima T; Deguchi S; Nakai T; Kawasaki Y; Kioka K
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1878-80. PubMed ID: 26805203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
    Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
    Fukubayashi K; Tanaka M; Izumi K; Watanabe T; Fujie S; Kawasaki T; Yoshimaru Y; Tateyama M; Setoyama H; Naoe H; Kikuchi K; Sasaki Y
    Cancer Med; 2015 Aug; 4(8):1214-23. PubMed ID: 26044168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
    Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
    Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
    Kang MK; Park JG; Lee HJ
    Medicine (Baltimore); 2018 Apr; 97(17):e0611. PubMed ID: 29703062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib plus cisplatin for hepatocellular carcinoma.
    Brower V
    Lancet Oncol; 2016 Oct; 17(10):e424. PubMed ID: 27617663
    [No Abstract]   [Full Text] [Related]  

  • 17. Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.
    Ahn SY; Lee HS; Kweon YO; Tak WY; Park SY
    Dig Dis Sci; 2013 May; 58(5):1428-32. PubMed ID: 23306847
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
    Francini E; Bianco V
    Hepatology; 2014 Aug; 60(2):764-5. PubMed ID: 25187926
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.
    Hagihara A; Ikeda M; Ueno H; Morizane C; Kondo S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Suzuki E; Katayama K; Imanaka K; Tamai C; Inaba Y; Sato Y; Kato M; Okusaka T
    Cancer Sci; 2014 Mar; 105(3):354-8. PubMed ID: 24438504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which treatment modality should we choose for advanced hepatocellular carcinoma?
    Kim DY
    Korean J Hepatol; 2010 Dec; 16(4):353-4. PubMed ID: 21415577
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.